Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial

Table 3 Reduction of maximal pain per migraine day

Intensity (SD)	Verum	Placebo	P value
	N = 55	N = 57
Baseline	2.71 (0.458)	2.70 (0.533)	-
Treatment 1st month	2.55 (0.503)	2.63 (0.620)	0.17
Treatment 2nd month	2.44 (0.572)	2.53 (0.630)	0.53
Treatment 3rd month	2.47 (0.639)	2.64 (0.520)	0.03
Patients (%)	Verum	Placebo	P value
	N = 55	N = 57
Baseline			-
- mild	0 (0)	2 (3.5)
- moderate	16 (29.1)	13 (22.8)
- severe	39 (70.9)	42 (73.7)
Treatment 3rd month			0.03
- mild	4 (7.3)	1 (1.8)
- moderate	20 (36.4)	18 (31.6)
- severe	29 (52.7)	37 (64.9)

ISSN: 1129-2377